Rankings
▼
Calendar
SYRE Q2 2025 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
SYRE
Spyre Therapeutics, Inc.
$3B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$42M
Net Income
-$37M
EPS (Diluted)
$-0.60
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$47M
Free Cash Flow
-$47M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$539M
Total Liabilities
$83M
Stockholders' Equity
$456M
Cash & Equivalents
$82M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$42M
-$44M
+5.0%
Net Income
-$37M
-$39M
+5.5%
← FY 2025
All Quarters
Q3 2025 →